The Effect of K _ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers.

ABSTRACT:

Background

Calcitonin gene-related peptide (CGRP) dilates cranial arteries and triggers headache. The CGRP signaling pathway is partly dependent on activation of ATP-sensitive potassium (K _ATP ) channels. Here, we investigated the effect of the K _ATP channel blocker glibenclamide on CGRP-induced headache and vascular changes in healthy volunteers.

Methods

In a randomized, double-blind, placebo-controlled, cross-over study, 20 healthy volunteers aged 18-27 years were randomly allocated to receive an intravenous infusion of 1.5 μg/min CGRP after oral pretreatment with glibenclamide (glibenclamide-CGRP day) or placebo (placebo-CGRP day). The primary endpoints were the difference in incidence of headache and the difference in area under the cu

SUBMITTER: Coskun H 

PROVIDER: S-EPMC8226177 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature